{
    "clinical_study": {
        "@rank": "124438", 
        "acronym": "Nanogam", 
        "arm_group": {
            "arm_group_label": "Intravenous immunoglobulin infusion", 
            "arm_group_type": "Experimental", 
            "description": "One intravenous infusion with Nanogam 50 mg/ml and 4 with Nanogam 100 mg/ml (0.2-0.8 g/kg)"
        }, 
        "brief_summary": {
            "textblock": "Intravenous immunoglobulin (IVIG) is used for treatment of a heterogeneous group of immune\n      related disorders both as immune-replacement and immune-modulating therapy. Sanquin\n      developed a 100 mg/ml IVIg product (Nanogam 100 mg/ml). Patient will receive one infusion\n      with Nanogam 50 mg/ml as they used to (same dose) and subsequently 4 infusions with Nanogam\n      100 mg/ml (same dose). Aim is to show bioequivalency between the 50 mg/ml and the 100 mg/ml\n      product of Sanquin."
        }, 
        "brief_title": "Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Immunodeficiency", 
        "condition_browse": {
            "mesh_term": "Immunologic Deficiency Syndromes"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Primary a- or hypogammaglobulinemia, particularly patients with XLA or CVID\n\n          -  Stabilised on treatment with Nanogam 50 mg/ml with 2-4 weeks intervals in an hospital\n             or at home and willing to be treated with 1 infusion of Nanogam 50 mg/ml and 4\n             infusions of Nanogam 100 mg/ml at the hospital\n\n          -  A stable clinical situation (no activity of any other disease; a stable\n             immunoglobulin dose and frequency)\n\n          -  Age >= 18 years\n\n          -  The patient has signed the consent form\n\n        Exclusion Criteria:\n\n          -  Known with allergic reactions against human plasma or plasma products\n\n          -  Having an ongoing progressive disease, including HIV infection\n\n          -  Pregnancy or lactation\n\n          -  Known with insufficiency of coronary or cerebral circulation\n\n          -  Having renal insufficiency (plasma creatinin > 115\u00b5mol/L)\n\n          -  Having IgA deficiency and anti-IgA antibodies have been detected"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01985373", 
            "org_study_id": "MD2012.02", 
            "secondary_id": "2012-005727-32"
        }, 
        "intervention": {
            "arm_group_label": "Intravenous immunoglobulin infusion", 
            "description": "Blood samples are drawn before infusion with Nanogam 50 and Nanogam 100 mg/ml and IgG levels are determined to study PK", 
            "intervention_name": "Intravenous immunoglobulin infusion", 
            "intervention_type": "Drug", 
            "other_name": "Nanogam"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Immunoglobulins", 
                "Antibodies", 
                "Immunoglobulins, Intravenous", 
                "Rho(D) Immune Globulin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "intravenous immunoglobulin", 
            "pharmacokinetics", 
            "10% IVIG"
        ], 
        "lastchanged_date": "November 8, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Den Bosch", 
                        "country": "Netherlands"
                    }, 
                    "name": "Jeroen Bosch Ziekenhuis"
                }, 
                "investigator": {
                    "last_name": "E de Vries, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Groningen", 
                        "country": "Netherlands"
                    }, 
                    "name": "UMCG"
                }, 
                "investigator": {
                    "last_name": "A Rutgers, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leiden", 
                        "country": "Netherlands"
                    }, 
                    "name": "LUMC"
                }, 
                "investigator": {
                    "last_name": "M H Haverkamp, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nijmegen", 
                        "country": "Netherlands"
                    }, 
                    "name": "UMC St. Radboud"
                }, 
                "investigator": {
                    "last_name": "M van Deuren, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pharmacokinetics and Safety of the Intravenous Human Immunoglobulin Product Nanogam 100 mg/ml", 
        "overall_contact": {
            "email": "i.kleinebudde@sanquin.nl", 
            "last_name": "Ilona Kleine Budde, PhD"
        }, 
        "overall_official": {
            "affiliation": "LUMC", 
            "last_name": "F P Kroon, PhD, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Comparison IVIG 5% and 10%", 
                "measure": "IgG trough levels", 
                "safety_issue": "No", 
                "time_frame": "before infusion"
            }, 
            {
                "description": "Comparison IVIG 5% and 10%", 
                "measure": "plasma concentration-time curve", 
                "safety_issue": "No", 
                "time_frame": "predose, 1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days post-dose"
            }, 
            {
                "description": "Comparison IVIG 5% and 10%", 
                "measure": "half-life", 
                "safety_issue": "No", 
                "time_frame": "predose, 1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days post-dose"
            }, 
            {
                "description": "Comparison IVIG 5% and 10%", 
                "measure": "area under the curve", 
                "safety_issue": "No", 
                "time_frame": "predose, 1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days post-dose"
            }, 
            {
                "description": "Comparison IVIG 5% and 10%", 
                "measure": "volume of distribution", 
                "safety_issue": "No", 
                "time_frame": "predose, 1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days post-dose"
            }, 
            {
                "description": "Comparison IVIG 5% and 10%", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "predose, 1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days post-dose"
            }, 
            {
                "description": "Comparison IVIG 5% and 10%", 
                "measure": "Tmax", 
                "safety_issue": "No", 
                "time_frame": "predose, 1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days post-dose"
            }, 
            {
                "description": "Comparison IVIG 5% and 10%", 
                "measure": "elimination rate constant(s)", 
                "safety_issue": "No", 
                "time_frame": "predose, 1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01985373"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "number and type", 
            "measure": "Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "from first till 3 weeks after last infusion (11-19 weeks dependent on infusion frequency)"
        }, 
        "source": "Sanquin", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanquin", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}